<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278223</url>
  </required_header>
  <id_info>
    <org_study_id>OTES-3301</org_study_id>
    <nct_id>NCT03278223</nct_id>
  </id_info>
  <brief_title>One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System</brief_title>
  <official_title>One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OTE North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OTE North America</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical performance of the contact lens care
      product Oté Sensation in a representative population of soft contact lens wearers. For
      comparison, a widely used FDA approved soft lens multipurpose solution will be used as a
      control. This control product has been tested in previous clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 1-month, 200-subject, double-masked (care product), bilateral, randomized,
      comparative study. Subjects will be clinically evaluated at the initial baseline visit (Visit
      1), then after 1 week and 1 month of lens wear having been randomly assigned to use one of
      six lens types and to either the test or control solutions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Subjective comfort. Subject grading comfort of lenses 0-10 (10 = cannot be felt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity (VA)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured using a Snellen (or LogMAR) chart. Visual Acuity will be measured to the nearest letter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Surface Wetting</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Lens surface wettability rated on the appearance of the lens surface and the drying time viewed with a slit lamp under low magnification. 0-4 scale (4 = Excellent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Film Deposits</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Any film deposits (protein/lipid) attached to the front surface of the lens. Scan the entire lens surface (10- 20X) for the presence of deposits. 0-4 (4= Heavy film)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal staining</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Assessed using a slit lamp by sector with fluorescein, blue light, yellow filter and full beam using a medium magnification. Cornea will be assessed by sector (C, N, T, I, S) 0-4 scale (4 = patch greater than 1mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limbal hyperemia</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Assessed using slit lamp with white light, low-medium magnification. 0-4 ( 4= Severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bulbar hyperemia</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Assessed using slit lamp with white light, low-medium magnification 0-4 ( 4= Severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Myopia</condition>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>Test solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test solution</intervention_name>
    <description>A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.</description>
    <arm_group_label>Test solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control solution</intervention_name>
    <description>A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.</description>
    <arm_group_label>Control solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a currently adapted soft contact lens wearer (&gt;1 month of lens wear).

          -  Be at least 18 years of age.

          -  Refractive astigmatism &lt;0.75 D in both eyes.

          -  Have clear corneas and be free of any anterior segment disorders.

          -  Be correctable through spherocylindrical refraction to 6/12 (20/40) (0.30 LogMAR) or
             better in each eye.

          -  Contact lens sphere requirement between +4.00 Dioptre and -8.00 D (inclusive).

          -  Require visual correction in both eyes (monovision allowed, no monofit).

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

               1. No amblyopia

               2. No strabismus

               3. No evidence of lid abnormality or infection

               4. No conjunctival abnormality or infection that would contraindicate contact lens
                  wear

               5. No clinically significant slit lamp findings (i.e. corneal staining, stromal
                  edema, staining, scarring, vascularization, infiltrates or abnormal opacities)

               6. No other active ocular disease.

        Exclusion Criteria:

          -  Require toric or multifocal contact lenses.

          -  Previously shown a sensitivity to any of the study solution components.

          -  Any systemic or ocular disease or allergies affecting ocular health.

          -  Using systemic or topical medications that will in the investigator's opinion affect
             ocular physiology or lens performance.

          -  Clinically significant (&gt;Grade 3) corneal staining, corneal stromal edema, corneal
             vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any
             other abnormality of the cornea that would contraindicate contact lens wear.

          -  Any corneal infiltrates or any corneal scarring or neovascularization within the
             central 5mm of the cornea.

          -  Keratoconus or other corneal irregularity.

          -  Aphakia or amblyopia.

          -  Have undergone corneal refractive surgery or any anterior segment surgery.

          -  Abnormal lacrimal secretions.

          -  Has diabetes.

          -  Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an
             immunosuppressive disease (e.g., HIV).

          -  History of chronic eye disease (e.g. glaucoma).

          -  Pregnant or lactating or planning a pregnancy at the time of enrolment.

          -  Participation in any concurrent clinical trial or in last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances L Nicklin, Bsc, MCOptom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visioncare Research Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Golden Vision</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacco Eye Group</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optometry Group PLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frazier Vision, Inc.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesite</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG1 1EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leightons and Tempany</name>
      <address>
        <city>Poole</city>
        <state>Bournemouth</state>
        <zip>BH15 1AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brock and Houlford</name>
      <address>
        <city>Chew Magna</city>
        <state>Bristol</state>
        <zip>BS40 8PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrold Opticians</name>
      <address>
        <city>Uxbridge</city>
        <state>Middlesex</state>
        <zip>UB8 1JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Contact</name>
      <address>
        <city>Eastcote</city>
        <state>Pinner</state>
        <zip>HA5 1RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visioncare Research Ltd</name>
      <address>
        <city>Farnham</city>
        <state>Surrey</state>
        <zip>GU9 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multipurpose Contact Lens Care System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Biguanides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

